Efecto citoprotector cardíaco y extracardíaco del péptido GHRP6
Danay Cibrián(Instituto de Salud Carlos III), Jose Ricardo Suarez(Centro de Ingeniería Genética y Biotecnología), Viviana Falcón(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Juan Valiente(Instituto de Cardiología y Cirugía Cardiovascular), Luis Guevara(Hermanos Ameijeiras Hospital), Jorge Berlanga(Centro de Ingeniería Genética y Biotecnología), Diana García(Centro de Ingeniería Genética y Biotecnología), Olga Sonia(University of Havana)
Biotecnología aplicada
January 1, 2008
Cited by 3
Related Papers
CD69: from activation marker to metabolic gatekeeper
|European Journal of Immunology|2017|935
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139